Basic Information

Gene symbol MIR155 Synonyms MIRN155, miRNA155, mir-155 Type of gene ncRNA
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description microRNA 155

GTO ID GTC0456
Trial ID NCT03713320
Disease T-Cell Lymphoma | Mycosis Fungoides
Altered gene miR-155
Therapeutic/Target gene Target gene
TherapyOligonucleotide
Treatment Cobomarsen|MRG-106
PhasePhase2
Recruitment statusTerminated
TitleSOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
Year2019
CountryAustralia|Belgium|Canada|France|Italy|Spain|United Kingdom|United States
Company sponsormiRagen Therapeutics, Inc.
Other ID(s)MRG106-11-201|2018-000727-13

Clinical Result

Cohort1: Cobomarsen
Administration route intravenous infusion
Dosage Cobomarsen, 282mg, Days 1, 3, 5, 8, and weekly thereafter
Pts 19
Age Adult, Older_Adult
Outcome 0(CR); 15.8(ORR)
Adverse reactions 0/19(All-cause mortality); 2/19(Infections and infestations; Injury, poisoning and procedural complications)
References PMID: 33085815 | 32632956
Cohort2: Vorinostat
Administration route oral
Dosage Vorinostat, 400mg, once daily
Pts 18
Age Adult, Older_Adult
Outcome Percentage of Subjects Achieving an Objective Skin Response of at Least 4 Months Duration (ORR4):16.7; 33.3(Objective Response Rate1); 16.7(Objective Response Rate4)
Adverse reactions 0/18(All-cause mortality); 1/18(Injury, poisoning and procedural complications)
References PMID: 33085815 | 32632956
Cohort3: Vorinostat,Cobomarsen
Administration route intravenous infusion
Dosage Cobomarsen, 282mg, Days 1, 3, 5, 8, and weekly thereafter
Pts 7
Age Adult, Older_Adult
Adverse reactions No serious clinical adverse events
References PMID: 33085815 | 32632956

Relationship Graph

Overview of Knowledge Graph